Company Overview
Company Type: Public Company
Website: www.acrobiosystems.cn
Number of Employees: 688
Ticker: 301080 (SZSE)
Year Founded: 2010


Business Description
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization. The company was founded in 2010 and is based in Beijing, China.

Financial Information (Currency: CAD, in mm) 
Total Revenue
96.8
Market Capitalization
1,584.8
TEV/Total Revenue
12.6x
EBITDA
20.6
Total Enterprise Value
1,222.7
TEV/EBITDA
51.7x
EBIT
17.3
Cash & ST Invst.
374.6
P/Diluted EPS Before Extra
67.8x
Net Income
35.1
Total Debt
12.4
Price/Tang BV
3.3x
Capital Expenditure
(57.5)
Total Assets
513.0
Total Debt/EBITDA
0.5x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Sep-28-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
-
-
0.33
0.42
0.33
Revenue (mm)
-
-
107.31
135.43
107.31
EBITDA (mm)
-
-
40.50
56.82
40.50

Forward Multiples (Current FY)

Price/Earnings
40.13x
TEV/REV
11.39x
TEV/EBITDA
30.19x
P/BV
3.12x

Non-Periodic Estimates

Recommendation
Buy (1.25)
Target Price
14.81
Potential Upside
12.12%


Key Professionals
Name
Title
Chen, Yiding 
GM & Chairman of the Board
Lin, Tao 
Deputy GM, CFO & Secretary of the Board of Directors
Huang, Xu 
Deputy GM & Director
Miao, Jingyun 
Deputy GM & Director

Key Board Members
Name
Title
Chen, Yiding 
GM & Chairman of the Board
Huang, Xu 
Deputy GM & Director
Miao, Jingyun 
Deputy GM & Director
Yan, Zhangwei 
Chairman of the Supervisory Board
Li, Yang 
Non-Independent Director
Liu, Feng 
Independent Director
Xu, Juanhong 
Independent Director
Yong, Zhang 
Independent Director
Qu, Wenting 
Non-Employee Supervisor
Yu, Yangyang 
Non-employee Supervisor


Primary Industry Classification
Biotechnology


Primary Office Location
Building 4, Building 5 Floor 4 No. 8 Hongda North Road, Daxing District Beijing Economic and Technological Devel | Beijing | 100176 | China
Phone: 86 10 5339 5173   Fax: 86 40 0887 5666

Current and Pending Investors
Breakthrough Capital, Neovision Capital, Shenzhen Co-win Venture Capital Investments Limited, Shenzhen Sharing Growth Investment Management Co., Ltd., Tibet Cowin Venture Capital Co., Ltd., Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 13.21
Market Cap (mm)
1,584.8
Open
 13.24
Shares Out. (mm)
120.0
Previous Close
 13.21
Float %
50.2%
Change on Day
(0.04)
Shares Sold Short (mm)
-
Change % on Day
(0.3)%
Dividend Yield %
1.4%
Day High/Low
 13.39/ 13.06
Diluted EPS Excl. Extra Items
0.19
52 wk High/Low
 17.44/ 10.66
P/Diluted EPS Before Extra
67.76x
Volume (mm)
1.06
Avg 3M Dly Vlm (mm)
1.04
Beta 5Y
-


 
Delayed Quote** | Last Updated on Sep-28-2023 12:00 AM (GMT-5)
SZSE:301080 - Common Stock


Index Membership
S&P Asia Pacific Emerging Between USD500 Million and USD2.5 Billion Index;S&P Asia Pacific Emerging BMI Index;S&P Asia Pacific Emerging BMI Health Care (Sector) Index;S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Asia Pacific EM SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Asia Pacific Emerging BMI Value Index;S&P Asia Pacific Emerging Under USD1.2 Billion Index;S&P Asia Pacific Emerging Under USD1.5 Billion Index;S&P China Between USD500 Million and USD2.5 Billion Index;S&P China BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Asia Pacific Emerging Between USD1 Billion and USD5 Billion Index;S&P Asia Pacific Emerging BMI Growth Index;S&P Asia Pacific Emerging Under USD3 Billion Index;S&P Asia Pacific Emerging SmallCap Index;S&P Asia Pacific Emerging SmallCap Value Index;S&P Asia Pacific BMI Emerging Under USD2 Billion Index;S&P China BMI Growth Index;S&P China BMI Health Care (Sector) Index;S&P China SmallCap Health Care (Sector) Index;S&P China SmallCap Index;S&P China Under USD1.5 Billion Index;S&P Asia Pacific Emerging SmallCap Growth Index;S&P China Under USD1.2 Billion Index;S&P Global Between USD1 Billion and USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Emerging Between USD500 Million and USD2.5 Billion Index;S&P Emerging SmallCap Growth Index;S&P Emerging SmallCap Value Index;S&P Emerging Under USD2 Billion Index;S&P Emerging Under USD3 Billion Index;S&P China BMI Index;S&P China BMI Value Index;S&P China SmallCap Growth Index;S&P Global Ex-Japan Under USD1.5 Billion Index;S&P Global Ex-Japan Under USD2 Billion Index;S&P Global Ex-U.S. BMI Growth Index;S&P Global Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Japan BMI Value Index;S&P Global BMI Index;S&P Emerging Between USD1 Billion and USD5 Billion Index;S&P Emerging BMI Index;S&P Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Emerging BMI Value Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-U.S. BMI Value Index;S&P Global Ex-U.S. SmallCap Growth Index;S&P Global Ex-U.S. SmallCap Value Index;S&P Global SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. Under USD1.2 Billion Index;S&P Global Ex-U.S. Under USD3 Billion Index;S&P Global Under USD2 Billion Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P Emerging SmallCap Index;S&P Emerging SmallCap Health Care (Sector) Index;S&P Emerging SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Emerging Under USD1.2 Billion Index;S&P Emerging Under USD1.5 Billion Index;S&P Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Japan Under USD1.2 Billion Index;S&P Pan Asia Ex-AU Ex-NZ Between USD1 Billion and USD5 Billion Index;S&P Pan Asia Ex-AU Ex-NZ SmallCap Growth Index;S&P Pan Asia Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Asia Ex-Japan BMI Value Index;S&P Pan Asia Ex-Japan SmallCap Health Care (Sector) Index;S&P Pan Asia SmallCap Index;S&P Pan Asia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Asia Under USD3 Billion Index;S&P Greater China BMI Value Index;S&P Greater China SmallCap Index;S&P Greater China Under USD1.5 Billion Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. SmallCap Index;S&P Global Ex-U.S. Under USD2 Billion Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Asia BMI Value Index;S&P Pan Asia Ex-AU Ex-NZ BMI Index;S&P Pan Asia Ex-Japan SmallCap Value Index;S&P Pan Asia SmallCap Value Index;S&P Pan Asia Under USD1.2 Billion Index;S&P Greater China BMI Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Value Index;S&P Global Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-U.S. BMI Index;S&P Greater China Under USD2 Billion Index;S&P Global Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. Under USD1.5 Billion Index;S&P Global Under USD1.5 Billion Index;S&P Pan Asia Ex-AU Ex-NZ SmallCap Index;S&P Pan Asia Ex-Japan SmallCap Growth Index;S&P Greater China Between USD1 Billion and USD5 Billion Index;S&P Greater China Under USD3 Billion Index;S&P Pan Asia BMI Index;S&P Pan Asia Ex-AU Ex-NZ SmallCap Value Index;S&P Pan Asia Ex-Japan BMI Growth Index;S&P Pan Asia Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Asia Ex-AU Ex-NZ Between USD500 Million and USD2.5 Billion Index;S&P Pan Asia Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Pan Asia Ex-Japan BMI Health Care (Sector) Index;S&P Pan Asia Under USD1.5 Billion Index;S&P Greater China SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Greater China BMI Growth Index;S&P Greater China SmallCap Health Care (Sector) Index;S&P Pan Asia Ex-Japan SmallCap Index;S&P Pan Asia Ex-Japan Under USD2 Billion Index;S&P Pan Asia Ex-Japan Under USD3 Billion Index;S&P Global BMI Growth Index;S&P Greater China Under USD1.2 Billion Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Pan Asia BMI Growth Index;S&P Pan Asia Ex-AU Ex-NZ Under USD3 Billion Index;S&P Pan Asia Ex-Japan Under USD1.5 Billion Index;S&P Pan Asia SmallCap Growth Index;S&P Pan Asia Between USD1 Billion and USD5 Billion Index;S&P Pan Asia Between USD500 Million and USD2.5 Billion Index;S&P Pan Asia Ex-AU Ex-NZ BMI Growth Index;S&P Pan Asia Ex-AU Ex-NZ BMI Value Index;S&P Pan Asia Ex-AU Ex-NZ Under USD1.5 Billion Index;S&P Pan Asia Ex-AU Ex-NZ Under USD2 Billion Index;S&P Pan Asia Ex-Japan BMI Index;S&P Greater China BMI Index;S&P Greater China BMI Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Greater China SmallCap Growth Index;S&P Asia Pacific Emerging SmallCap Health Care (Sector) Index;S&P China Between USD1 Billion and USD5 Billion Index;S&P China SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P China SmallCap Value Index;S&P China Under USD2 Billion Index;S&P China Under USD3 Billion Index;S&P Emerging BMI Growth Index;S&P Emerging BMI Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global BMI Value Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P Global SmallCap Value Index;S&P Global Under USD1.2 Billion Index;S&P Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Asia Ex-AU Ex-NZ Under USD1.2 Billion Index;S&P Pan Asia Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Pan Asia Ex-Japan Under USD1.2 Billion Index;S&P Pan Asia SmallCap Health Care (Sector) Index;S&P Pan Asia Under USD2 Billion Index;S&P Greater China Between USD500 Million and USD2.5 Billion Index;S&P Greater China SmallCap Value Index;S&P Pan Asia Ex-Japan, AU, NZ BMI Index;S&P Pan Asia X AU X NZ BMI Health Care (Sector) Index;S&P Pan Asia X AU X NZ BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Pan Asia X AU X NZ SmallCap Health Care (Sector) Index;S&P Pan Asia X AU X NZ SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Asia Pacific Emerging Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P China Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Emerging Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Greater China Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Pan Asia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Pan Asia Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Emerging Ex-Africa BMI;S&P Emerging Ex-Africa SmallCap;S&P Pan Asia Ex-NZ BMI;S&P Pan Asia Ex-NZ SmallCap;S&P Pan Asia ex-JP, AU, NZ, India BMI;S&P Pan Asia ex-JP, AU, NZ, India SmallCap;S&P Global Ex-Australia & New Zealand Between USD1 Billion and USD5 Billion;S&P China A BMI;S&P Emerging Plus BMI;S&P/IFCI China;S&P/IFCI China Health Care (Sector);S&P/IFCI China Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI China SmallCap;S&P/IFCI Asia Ex-Malaysia;S&P/IFCI Asia Ex-Malaysia Health Care (Sector);S&P/IFCI Asia Ex-Malaysia Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Asia Ex-Malaysia SmallCap;S&P/IFCI Composite;S&P/IFCI Composite Health Care (Sector);S&P/IFCI Composite Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Composite SmallCap;S&P/IFCI Asia;S&P/IFCI Asia Health Care (Sector);S&P/IFCI Asia Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Asia SmallCap;S&P/IFCI Composite Ex-Malaysia;S&P/IFCI Composite Ex-Malaysia Health Care (Sector);S&P/IFCI Composite Ex-Malaysia Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Composite Ex-Malaysia SmallCap;S&P/IFCI China Growth;S&P/IFCI China Growth Health Care (Sector);S&P/IFCI China Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Asia Ex-Malaysia Growth;S&P/IFCI Asia Ex-Malaysia Growth Health Care (Sector);S&P/IFCI Asia Ex-Malaysia Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Composite Growth;S&P/IFCI Composite Growth Health Care (Sector);S&P/IFCI Composite Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Asia Growth;S&P/IFCI Asia Growth Health Care (Sector);S&P/IFCI Asia Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Composite Ex-Malaysia Growth;S&P/IFCI Composite Ex-Malaysia Growth Health Care (Sector);S&P/IFCI Composite Ex-Malaysia Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P/IFCI China Value;S&P/IFCI China Value Health Care (Sector);S&P/IFCI China Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Asia Ex-Malaysia Value;S&P/IFCI Asia Ex-Malaysia Value Health Care (Sector);S&P/IFCI Asia Ex-Malaysia Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Composite Value;S&P/IFCI Composite Value Health Care (Sector);S&P/IFCI Composite Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Asia Value;S&P/IFCI Asia Value Health Care (Sector);S&P/IFCI Asia Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P/IFCI Composite Ex-Malaysia Value;S&P/IFCI Composite Ex-Malaysia Value Health Care (Sector);S&P/IFCI Composite Ex-Malaysia Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Baisi Medical Diagnostic Technology (Beijing) Co., Ltd.
Baisi Medical Diagnostic Technology (Beijing) Co., Ltd. was founded in 2021 and is based in Beijing, China. Baisi Medical Diagnostic Technology (Beijing) Co., Ltd. operates as a subsidiary of Acrobiosystems Co.,Ltd.

Asia / Pacific
-
-
-
-
Shanghai Biaodu Biotech Co., Ltd.
Shanghai Biaodu Biotech Co., Ltd. engages in biological drug R&D and provides clinical translational research services. The company was founded in 2021 and is based in Shanghai, China.

Asia / Pacific
Health Care Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-18-2023
-
Buyback
Target
Acrobiosystems Co.,Ltd. (SZSE:301080)


4.18
Sep-23-2022
Sep-23-2022
Private Placement
Buyer
Shanghai Biaodu Biotech Co., Ltd.
Baotou Hongyuan Investment Management Consultation Co., Ltd.,Huaige Capital,Acrobiosystems Co.,Ltd. (SZSE:301080)

3.00
Mar-18-2022
Mar-24-2022
Private Placement
Buyer
Baisi Medical Diagnostic Technology (Beijing) Co., Ltd.
Acrobiosystems Co.,Ltd. (SZSE:301080),Beijing Juli Changxin Enterprise Management Consulting Partnership (Limited Partnership)

3.14
Jan-20-2021
Oct-11-2021
Public Offering
Target
Acrobiosystems Co.,Ltd. (SZSE:301080)


348.81
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-03-2023
Changes in Company Bylaws/Rules
Acrobiosystems Co.,Ltd. Approves Amendments to the Articles of Association
Aug-03-2023
Executive/Board Changes - Other
Acrobiosystems Co.,Ltd. Approves Board Elections
Aug-02-2023
Special/Extraordinary Shareholders Meeting
Acrobiosystems Co.,Ltd., Special/Extraordinary Shareholders Meeting, Aug 02, 2023
Jul-17-2023
Buyback Transaction Announcements
Acrobiosystems Co.,Ltd. (SZSE:301080) announces an Equity Buyback for CNY 30 million worth of its shares.
Jul-17-2023
Buyback Transaction Announcements
Acrobiosystems Co.,Ltd. authorizes a Buyback Plan.


Advisors
Most Recent Auditor
Rongcheng Accounting Firm (Special General Partnership)
Public Offering Advisors
Llinks Law Offices, RSM China


Most Recent Auditor
Rongcheng Certified Public Accountants


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Haitong International Research Limited
Meng, Kehan
Sep 27, 2023 01:40 AM
301080
Acrobiosystems (301080 CH)：Overseas Business Continues Rapid Growth, Staff Expansion Impacts Short-term Performance—Maintain OP & Cut TP by 38%
Reports
9
Haitong International Research Limited
Meng, Kehan
Sep 25, 2023 08:20 AM
301080
百普赛斯 (301080 CH)：海外业务保持高速增长，人员扩张拖累短期业绩—维持优于大市; 下调目标价38%（Acrobiosystems：Overseas Business Continues Rapid Growth, Staff Expansion Impacts Short-term Performance—Maintain OP & Cut TP by 38%）
Reports
11
China International Capital Corporation Limited
Fu, Jiaying
Sep 18, 2023 07:55 AM
301080
百普赛斯(301080.SZ) - 首次覆盖跑赢行业 - 生物试剂蛋白类赛道基石，全球化布局驱动增长(2023-09-18)
Reports
30
China International Capital Corporation Limited
Fu, Jiaying
Sep 18, 2023 07:51 AM
301080
百普赛斯(301080.SZ) - 首次覆盖跑赢行业 - 生物试剂蛋白类赛道基石，全球化布局驱动增长(2023-09-18)
Reports
30
Huatai Research
Dai, Wen
Sep 15, 2023 07:24 AM
301080
【Huatai Research】Acrobiosystems (301080 CH, BUY): Revenue From Regular Business Grew Fast, Profit Growth Strained
Reporting Results*
6
Guosen Securities Co., Ltd.
Zhang, Jiabo
Aug 30, 2023 08:56 AM
301080
常规业务营收同比增长 33%，利润端短期略承压
Reports
7
Guosen Securities Co., Ltd.
Zhang, Jiabo
Aug 30, 2023 08:54 AM
301080
常规业务营收同比增长 33%，利润端短期略承压
Reports
7
Huatai Research
Dai, Wen
Aug 28, 2023 08:12 PM
301080
【华泰研究 — 医药健康】百普赛斯 (301080 CH, 买入): 常规收入高增长，表观利润增速承压
Reports
6
Guosen Securities Co., Ltd.

Aug 15, 2023 05:04 AM
301080
晨 会 纪 要 - 晨会主题
Reports
20
Guosen Securities Co., Ltd.

Aug 15, 2023 05:02 AM
301080
晨 会 纪 要 - 晨会主题
Reports
20


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Chen, Yiding 

28,240,752

23.53

373.4

Jul-17-2023


Tianjin Acrobiosystems Enterprise Management Consulting Partnership Enterprise (Limited Partnership)

11,985,762

9.99

158.5

Jul-17-2023


Miao, Jingyun 

10,707,678

8.92

141.6

Jul-17-2023


Yan, Zhangwei 

5,398,356

4.50

71.4

Jul-17-2023


National Council for Social Security Fund

5,084,491

4.24

67.2

Jul-17-2023


Zhong Ou Fund Management Co., Ltd

4,348,656

3.62

57.5

Sep-30-2022


JP Morgan Asset Management

4,161,884

3.47

55.0

Mar-31-2023


Shanghai Lanting Investment Management Co., Ltd.

3,763,529

3.14

49.8

Sep-30-2022


Neovision Capital

3,438,503

2.87

45.5

Jul-17-2023


ICBC Credit Suisse Asset Management Co., Ltd.

2,809,950

2.34

37.2

Jun-30-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Tianjin Bapu Jiale Enterprise Management Consulting Partnership Enterprise (Limited Partnership)
1,834,411
1,834,411
National Council for Social Security Fund
5,084,491
417,149
Guotai Asset Management Company Limited
58,973
55,798
Harvest Fund Management Co. Ltd.
30,850
22,300
Penghua Fund Management Co., Ltd.
9,250
9,250

Top Sellers
Sellers
Common Stock Equivalent Held
Change
GF Fund Management Co., Ltd.
35,150
(1,867,150)
ABC-CA Fund Management Co., Ltd.
268,515
(420,487)
Shuntian Xinrong International Investment (Beijing) Co., Ltd.
1,270,000
(393,800)
UBS SDIC Fund Management Co., Ltd.
0
(35,550)
Premia Partners
39,168
(28,520)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-09-2023
Special/Extraordinary Shareholders Meeting
Oct-25-2023
Estimated Earnings Release Date (S&P Global Derived)
Oct-30-2023
Earnings Release Date
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Chen, Yiding 
GM & Chairman of the Board
86 10 5339 5173
86 40 0887 5666

Huang, Xu 
Deputy GM & Director
86 10 5339 5173
86 40 0887 5666

Miao, Jingyun 
Deputy GM & Director
86 10 5339 5173
86 40 0887 5666

Yan, Zhangwei 
Chairman of the Supervisory Board
86 10 5339 5173
86 40 0887 5666

Li, Yang 
Non-Independent Director
86 10 5339 5173
86 40 0887 5666

Liu, Feng 
Independent Director
86 10 5339 5173
86 40 0887 5666

Xu, Juanhong 
Independent Director
86 10 5339 5173
86 40 0887 5666

Yong, Zhang 
Independent Director
86 10 5339 5173
86 40 0887 5666

Qu, Wenting 
Non-Employee Supervisor
86 10 5339 5173
86 40 0887 5666

Yu, Yangyang 
Non-employee Supervisor
86 10 5339 5173
86 40 0887 5666

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Chen, Yiding 
GM & Chairman of the Board
86 10 5339 5173
86 40 0887 5666

Lin, Tao 
Deputy GM, CFO & Secretary of the Board of Directors
86 10 5339 5173
86 40 0887 5666

Huang, Xu 
Deputy GM & Director
86 10 5339 5173
86 40 0887 5666

Miao, Jingyun 
Deputy GM & Director
86 10 5339 5173
86 40 0887 5666

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
